Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Marc A. Gavin is active.

Publication


Featured researches published by Marc A. Gavin.


Journal of Experimental Medicine | 2005

TGF-β1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells

Julien C. Marie; John J. Letterio; Marc A. Gavin; Alexander Y. Rudensky

Transforming growth factor (TGF)-β1 is a major pluripotential cytokine with a pronounced immunosuppressive effect and its deficiency results in lethal autoimmunity in mice. However, mechanisms of its immunosuppressive action are not completely understood. Here, we report that TGF-β1 supports the maintenance of Foxp3 expression, regulatory function, and homeostasis in peripheral CD4+CD25+ regulatory T (T reg) cells, but is not required for their thymic development. We found that in 8–10-d-old TGF-β1–deficient mice, peripheral, but not thymic, T reg cells are significantly reduced in numbers. Moreover, our experiments suggest that a defect in TGF-β–mediated signaling in T reg cells is associated with a decrease in Foxp3 expression and suppressor activity. Thus, our results establish an essential link between TGF-β1 signaling in peripheral T reg cells and T reg cell maintenance in vivo.


Nature | 2007

Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells

Ye Zheng; Steven Z. Josefowicz; Arnold Kas; Tin-Tin Chu; Marc A. Gavin; Alexander Y. Rudensky

Transcription factor Foxp3 (forkhead box P3), restricted in its expression to a specialized regulatory CD4+ T-cell subset (TR) with a dedicated suppressor function, controls TR lineage development. In humans and mice, Foxp3 deficiency results in a paucity of TR cells and a fatal breach in immunological tolerance, causing highly aggressive multi-organ autoimmune pathology. Here, through genome-wide analysis combining chromatin immunoprecipitation with mouse genome tiling array profiling, we identify Foxp3 binding regions for ∼700 genes and for an intergenically encoded microRNA. We find that a large number of Foxp3-bound genes are up- or downregulated in Foxp3+ T cells, suggesting that Foxp3 acts as both a transcriptional activator and repressor. Foxp3-mediated regulation unique to the thymus affects, among others, genes encoding nuclear factors that control gene expression and chromatin remodelling. In contrast, Foxp3 target genes shared by the thymic and peripheral TR cells encode primarily plasma membrane proteins, as well as cell signalling proteins. Together, our studies suggest that distinct transcriptional sub-programmes implemented by Foxp3 establish TR lineage during differentiation and its proliferative and functional competence in the periphery.


Science | 2006

An antigen produced by splicing of noncontiguous peptides in the reverse order

Edus H. Warren; Nathalie Vigneron; Marc A. Gavin; Pierre Coulie; Vincent Stroobant; Alexandre Dalet; Scott S. Tykodi; Suzanne M. Xuereb; Jeffrey K. Mito; Stanley R. Riddell; Benoît Van den Eynde

CD8-positive T lymphocytes recognize peptides that are usually derived from the degradation of cellular proteins and are presented by class I molecules of the major histocompatibility complex. Here we describe a human minor histocompatibility antigen created by a polymorphism in the SP110 nuclear phosphoprotein gene. The antigenic peptide comprises two noncontiguous SP110 peptide segments spliced together in reverse order to that in which they occur in the predicted SP110 protein. The antigenic peptide could be produced in vitro by incubation of precursor peptides with highly purified 20S proteasomes. Cutting and splicing probably occur within the proteasome by transpeptidation.


Immunity | 1995

Increased peptide promiscuity provides a rationale for the lack of N regions in the neonatal T cell repertoire

Marc A. Gavin; Michael J. Bevan

Making use of mice deficient for terminal deoxynucleotidyl transferase (TdT) expression and a random peptide library, we have examined the diversity and peptide specificity of the neonatal T cell repertoire specific for a single H-2Db-restricted peptide. Consistent with the predicted decrease in repertoire diversity, polyclonal CTL lines and individual clones from different TdTo mice are more similar to each other than those from different wild-type mice in terms of their fingerprints of cross-reactivity to the library and their TCR sequences. We have also found that several TdTo CTL clones cross-react with many more library peptides than wild-type CTL clones. In a few instances, the degree of peptide promiscuity correlates with TCR sequence characteristics such as N region addition and homology-directed recombination, but not CDR3 loop length. Based on epitope titrations for each clone, TCR affinity for antigen is consistently high; thus, this reduced specificity for peptide may coincide with an accentuated affinity for the alpha helices of the MHC. Peptide promiscuity in the neonate may allow the relatively small numbers of T cells in the periphery to protect against a broader range of pathogens.


Cell | 2006

FOXP3 and NFAT: Partners in Tolerance

Alexander Y. Rudensky; Marc A. Gavin; Ye Zheng

Regulatory T cells suppress autoimmune responses to self-antigens. Recent studies, including one in this issue of Cell (Wu et al., 2006), suggest that the ability of T cells to choose between launching a productive immune response, functional inactivation, or developing into regulatory T cells depends upon the interplay of the key transcriptional regulators FOXP3 and NFAT.


Clinical Cancer Research | 2007

Effects of the Administration of High-Dose Interleukin-2 on Immunoregulatory Cell Subsets in Patients with Advanced Melanoma and Renal Cell Cancer

Hans J. van der Vliet; Henry B. Koon; Simon Yue; Burak Uzunparmak; Virginia Seery; Marc A. Gavin; Alexander Y. Rudensky; Michael B. Atkins; Steven P. Balk; Mark A. Exley

Purpose: High-dose recombinant human interleukin-2 (IL-2) therapy is of clinical benefit in a subset of patients with advanced melanoma and renal cell cancer. Although IL-2 is well known as a T-cell growth factor, its potential in vivo effects on human immunoregulatory cell subsets are largely unexplored. Experimental Design: Here, we studied the effects of high-dose IL-2 therapy on circulating dendritic cell subsets (DC), CD1d-reactive invariant natural killer T cells (iNKT), and CD4+CD25+ regulatory-type T cells. Results: The frequency of both circulating myeloid DC1 and plasmacytoid DC decreased during high-dose IL-2 treatment. Of these, only a significant fraction of myeloid DC expressed CD1d. Although the proportion of Th1-type CD4− iNKT increased, similarly to DC subsets, the total frequency of iNKT decreased during high-dose IL-2 treatment. In contrast, the frequency of CD4+CD25+ T cells, including CD4+Foxp3+ T cells, which have been reported to suppress antitumor immune responses, increased during high-dose IL-2 therapy. However, there was little, if any, change of expression of GITR, CD30, or CTLA-4 on CD4+CD25+ T cells in response to IL-2. Functionally, patient CD25+ T cells at their peak level (immediately after the first cycle of high-dose IL-2) were less suppressive than healthy donor CD25+ T cells and mostly failed to Th2 polarize iNKT. Conclusions: Our data show that there are reciprocal quantitative and qualitative alterations of immunoregulatory cell subsets with opposing functions during treatment with high-dose IL-2, some of which may compromise the establishment of effective antitumor immune responses.


Molecular and Cellular Biology | 2007

G Protein-Coupled Receptor 83 Is Dispensable for the Development and Function of Regulatory T Cells

Li-Fan Lu; Marc A. Gavin; Jeffrey P. Rasmussen; Alexander Y. Rudensky

ABSTRACT Global analyses of gene expression in regulatory T (Treg) cells, whose development is critically dependent upon the transcription factor Foxp3, have provided many clues as to the molecular mechanisms these cells employ to control immune responses and establish immune tolerance. Through these studies, G protein-coupled receptor 83 (GPR83) was found to be expressed at high levels in Treg-cell populations. However, its function remained unclear. Recently, it has been suggested that GPR83 is involved in the induction of Foxp3 expression in the peripheral nonregulatory Foxp3− CD4 T cells. To examine a role for GPR83 in Treg-cell biology, we generated and characterized GPR83-deficient mice. We have shown that GPR83 abolition does not result in measurable pathology or changes in the numbers or function of Foxp3+ Treg cells. Furthermore, while in vitro analysis suggested a potential involvement of GPR83 in transforming growth factor β-dependent Foxp3 induction, there was no difference in the ability of nonregulatory GPR83-deficient and nondeficient Foxp3− T cells to acquire Foxp3 expression in vivo. Collectively, our results demonstrate that GPR83 is dispensable for Treg-cell development and function.


Nature Immunology | 2002

Dual TCR T cells: gaining entry into the periphery.

Marc A. Gavin; Alexander Y. Rudensky

T cells bearing two different TCRs can be detrimental because the unselected TCR has the potential to cause autoimmunity. Evidence is now emerging that the unselected TCR may also be beneficial by expanding the TCR repertoire for foreign antigens.


Proceedings of the National Academy of Sciences of the United States of America | 2006

Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development

Marc A. Gavin; Troy R. Torgerson; Evan G. Houston; Paul deRoos; William Ho; Asbjørg Stray-Pedersen; Elizabeth L. Ocheltree; Philip D. Greenberg; Hans D. Ochs; Alexander Y. Rudensky


Journal of Experimental Medicine | 1993

Positive selection of CD8+ T cells induced by major histocompatibility complex binding peptides in fetal thymic organ culture.

Kristin A. Hogquist; Marc A. Gavin; Michael J. Bevan

Collaboration


Dive into the Marc A. Gavin's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Philip D. Greenberg

Fred Hutchinson Cancer Research Center

View shared research outputs
Top Co-Authors

Avatar

Stanley R. Riddell

Fred Hutchinson Cancer Research Center

View shared research outputs
Top Co-Authors

Avatar

Edus H. Warren

Fred Hutchinson Cancer Research Center

View shared research outputs
Top Co-Authors

Avatar

Brad H. Nelson

University of Washington

View shared research outputs
Top Co-Authors

Avatar

Claes Öhlén

University of Washington

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ye Zheng

University of Washington

View shared research outputs
Researchain Logo
Decentralizing Knowledge